News
AbbVie’s Skyrizi took home the top spot for most pharma brand ad impressions in April 2025, according to data released by ...
1d
Barchart on MSNAre Wall Street Analysts Predicting AbbVie Stock Will Climb or Sink?AbbVie Inc. (ABBV), headquartered in North Chicago, Illinois, is a biopharmaceutical company discovers, develops, ...
AbbVie snagged yet another spot among April’s highest TV ad spenders, as its Vraylar jumped two spots to eighth place with a ...
With the potential for pharmaceutical import tariffs spurring a rush of life sciences investments in the U.S., AbbVie is ...
AbbVie had a strong Q1 performance in its oncology, neuroscience, and immunology franchises. Read why I continue to rate ABBV ...
We came across a bullish thesis on AbbVie Inc. (ABBV) on Substack by Magnus Ofstad. In this article, we will summarize the ...
AbbVie raised its full-year profit forecast on Friday while downplaying the potential hit some analysts expect it to take ...
AbbVie Inc. beat revenue & EPS estimates, raised guidance due to Skyrizi & Rinvoq growth. Immunology shines; future ...
Drugmaker AbbVie plans to invest more than $10 billion in domestic manufacturing and other capabilities over the next decade, ...
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...
13d
Zacks.com on MSNAbbVie Beats on Q1 Earnings & Sales, Raises '25 EPS ViewABBV's first-quarter earnings and sales beat estimates. The company raises its EPS guidance based on the strong sales ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results